[Name] Hemotech [Sponsor] HemoBiotech [Description] 
Current approved for Phase I trials. HemoBiotech, based in Dallas, TX is developing HemoTech, a human blood substitute developed in 1985 by researchers, Mario Feola, MD and Jan Simoni, PHD, DVM from the Texas Tech University Health Sciences Center (TTUHSC). HemoBiotech has been able to identify and nullify the source of toxicity issues associated with previous blood substitute candidates. HemoTech, which is expected to be compatible will all blood types and a shelf life of 180+ days compared to 41 days for donated human blood. HemoTech's lack of toxicity is believed to be due to Hemobiotech's proprietary chemical modification of haemoglobin. The company believes the use of bovine blood provides an additional advantage over products developed from outdated human red blood cells or from perfluorochemicals (PFCs), as bovine blood is more readily available and more cost-effective to use. Limited tests have shown it to be clear of the vasoconstriction and inflammatory toxicity issues that have hampered competitors.